within Pharmacolibrary.Drugs.ATC.N;

model N05AG02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.18 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,
    adminCount     = 1,
    Vd             = 0.006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Pimozide is a typical antipsychotic drug of the diphenylbutylpiperidine class, primarily used in the treatment of chronic psychotic disorders such as Tourette's syndrome and schizophrenia. Although approved for use, it is less commonly prescribed today due to the risk of severe side effects, such as QT prolongation and arrhythmias.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Pergolizzi, JV, et al., &amp; Varrassi, G (2024). An update on pharmacotherapy for trigeminal neuralgia. <i>Expert review of neurotherapeutics</i> 24(8) 773–786. DOI:<a href=&quot;https://doi.org/10.1080/14737175.2024.2365946&quot;>10.1080/14737175.2024.2365946</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38870050/&quot;>https://pubmed.ncbi.nlm.nih.gov/38870050</a></p></li><li><p>Sallee, FR, et al., &amp; Perel, JM (1987). Pharmacokinetics of pimozide in adults and children with Tourette&#x27;s syndrome. <i>Journal of clinical pharmacology</i> 27(10) 776–781. DOI:<a href=&quot;https://doi.org/10.1002/j.1552-4604.1987.tb02995.x&quot;>10.1002/j.1552-4604.1987.tb02995.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3480904/&quot;>https://pubmed.ncbi.nlm.nih.gov/3480904</a></p></li><li><p>Desta, Z, et al., &amp; Flockhart, DA (1999). Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). <i>Clinical pharmacology and therapeutics</i> 65(1) 10–20. DOI:<a href=&quot;https://doi.org/10.1016/S0009-9236(99)70117-7&quot;>10.1016/S0009-9236(99)70117-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9951426/&quot;>https://pubmed.ncbi.nlm.nih.gov/9951426</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05AG02;
